Apoptotic liver injury, NAFLD activity and alanine aminotransferase (ALT) levels, as well as liver fibrosis significantly decreased by anti-TNFR1 compared to control-antibody treatment. The gene discussed is TNFRSF1A; the disease is metabolic dysfunction-associated steatotic liver disease.